Having trouble accessing articles? Reset your cache.

AML, safety data for magrolimab help Forty Seven shares regain ground

After disappointing investors with its first data on anti-CD47 mAb magrolimab in May, Forty Seven gained $1.20 (18%) to $8.01 on Wednesday with updated data showing slight improvements in AML response rates and a consistent safety profile.

In an abstract released ahead of next month’s American Society of Hematology (ASH)

Read the full 505 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE